Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BPMC Blueprint Medicines	$103.06 +8.1%	$91.36	$73.04 ▼ $121.90	$6.66B	0.83	785,709 shs	1.40 million shs
ROIV Roivant Sciences	$11.30 +6.4%	$10.52	$8.73 ▼ $13.06	$8.06B	1.23	5.59 million shs	8.43 million shs
RVMD Revolution Medicines	$39.08 +3.6%	$37.53	$29.17 ▼ $62.40	$7.28B	1.11	1.51 million shs	1.81 million shs
VCEL Vericel	$41.35 -1.8%	$41.77	$37.39 ▼ $63.00	$2.08B	1.31	411,817 shs	670,573 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BPMC Blueprint Medicines	-4.76%	-6.12%	+7.67%	+5.40%	-6.90%
ROIV Roivant Sciences	-1.30%	-2.66%	-5.09%	+2.31%	-1.94%
RVMD Revolution Medicines	+2.06%	-2.61%	-9.02%	-3.45%	-0.45%
VCEL Vericel	+0.07%	+2.51%	+8.67%	-15.16%	-12.24%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BPMC Blueprint Medicines	1.8259 of 5 stars	3.4	1.0	0.0	2.9	0.8	0.6
ROIV Roivant Sciences	2.3606 of 5 stars	3.5	3.0	0.0	2.2	2.5	0.0
RVMD Revolution Medicines	4.2854 of 5 stars	4.5	0.0	4.7	3.6	2.5	0.0
VCEL Vericel	2.9288 of 5 stars	3.5	3.0	0.0	2.2	0.8	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BPMC Blueprint Medicines	2.83	Moderate Buy	$126.56	22.80% Upside
ROIV Roivant Sciences	3.00	Buy	$17.50	54.87% Upside
RVMD Revolution Medicines	3.00	Buy	$67.08	71.66% Upside
VCEL Vericel	3.00	Buy	$61.14	47.87% Upside

Current Analyst Ratings Breakdown

Latest VCEL, ROIV, RVMD, and BPMC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/28/2025	ROIV Roivant Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
5/22/2025	VCEL Vericel	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$67.00 ➝ $67.00
5/14/2025	RVMD Revolution Medicines	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$73.00 ➝ $72.00
5/8/2025	RVMD Revolution Medicines	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$67.00
5/8/2025	RVMD Revolution Medicines	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$70.00 ➝ $75.00
5/8/2025	RVMD Revolution Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$87.00 ➝ $80.00
5/8/2025	RVMD Revolution Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$57.00 ➝ $57.00
5/2/2025	BPMC Blueprint Medicines	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$135.00 ➝ $135.00
5/1/2025	BPMC Blueprint Medicines	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$128.00
4/28/2025	BPMC Blueprint Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$133.00 ➝ $130.00
4/28/2025	RVMD Revolution Medicines	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$67.00 ➝ $67.00

(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BPMC Blueprint Medicines	$562.12M	11.84	N/A	N/A	$4.67 per share	22.07
ROIV Roivant Sciences	$122.59M	65.78	N/A	N/A	$7.76 per share	1.46
RVMD Revolution Medicines	$742K	9,810.45	N/A	N/A	$11.09 per share	3.52
VCEL Vericel	$238.54M	8.73	$0.01 per share	3,081.95	$4.73 per share	8.74

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BPMC Blueprint Medicines	-$67.09M	-$2.47	N/A	158.55	N/A	-13.19%	-77.49%	-20.84%	8/7/2025 (Estimated)
ROIV Roivant Sciences	$4.35B	-$0.15	N/A	N/A	N/A	-119.54%	-14.05%	-12.81%	5/29/2025 (Estimated)
RVMD Revolution Medicines	-$436.37M	-$4.00	N/A	N/A	N/A	N/A	-33.67%	-30.08%	8/6/2025 (Estimated)
VCEL Vericel	-$3.18M	$0.03	689.28	93.98	N/A	1.56%	1.48%	0.96%	8/7/2025 (Estimated)

Latest VCEL, ROIV, RVMD, and BPMC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/29/2025	Q4 2025	ROIV Roivant Sciences	-$0.16	-$0.31	-$0.15	-$0.29	$62.17 million	$7.57 million
5/8/2025	Q1 2025	VCEL Vericel	-$0.09	-$0.23	-$0.14	-$0.23	$53.86 million	$52.60 million
5/7/2025	Q1 2025	RVMD Revolution Medicines	-$1.12	-$1.13	-$0.01	-$1.13	N/A	N/A
5/1/2025	Q1 2025	BPMC Blueprint Medicines	-$0.42	-$0.74	-$0.32	$0.01	$158.31 million	$149.41 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BPMC Blueprint Medicines	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A
RVMD Revolution Medicines	N/A	N/A	N/A	N/A	N/A
VCEL Vericel	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BPMC Blueprint Medicines	1.15	2.85	2.80
ROIV Roivant Sciences	N/A	37.91	37.91
RVMD Revolution Medicines	N/A	14.24	14.24
VCEL Vericel	N/A	4.61	4.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BPMC Blueprint Medicines	N/A
ROIV Roivant Sciences	64.76%
RVMD Revolution Medicines	94.34%
VCEL Vericel	N/A

Insider Ownership

Company	Insider Ownership
BPMC Blueprint Medicines	4.21%
ROIV Roivant Sciences	7.90%
RVMD Revolution Medicines	8.20%
VCEL Vericel	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BPMC Blueprint Medicines	640	64.58 million	61.22 million	Optionable
ROIV Roivant Sciences	860	713.55 million	657.18 million	Optionable
RVMD Revolution Medicines	250	186.27 million	154.76 million	Optionable
VCEL Vericel	300	50.34 million	46.79 million	Optionable

VCEL, ROIV, RVMD, and BPMC Headlines

Recent News About These Companies

Vericel (NASDAQ:VCEL) Earns Overweight Rating from Stephens

May 25, 2025 | americanbankingnews.com

Vericel's (VCEL) Overweight Rating Reiterated at Stephens

May 24, 2025 | marketbeat.com

Vericel Co. (NASDAQ:VCEL) Shares Purchased by Deutsche Bank AG

May 24, 2025 | marketbeat.com

5VCEL : What Analysts Are Saying About Vericel Stock

May 23, 2025 | benzinga.com

Vericel Co. (NASDAQ:VCEL) Stock Position Cut by BNP Paribas Financial Markets

May 23, 2025 | marketbeat.com

Rafferty Asset Management LLC Lowers Stake in Vericel Co. (NASDAQ:VCEL)

May 22, 2025 | marketbeat.com

Lazard Asset Management LLC Purchases 5,923 Shares of Vericel Co. (NASDAQ:VCEL)

May 22, 2025 | marketbeat.com

Soleus Capital Management L.P. Purchases Shares of 80,696 Vericel Co. (NASDAQ:VCEL)

May 21, 2025 | marketbeat.com

Vericel Co. (NASDAQ:VCEL) Holdings Raised by D. E. Shaw & Co. Inc.

May 20, 2025 | marketbeat.com

Ameriprise Financial Inc. Sells 124,122 Shares of Vericel Co. (NASDAQ:VCEL)

May 19, 2025 | marketbeat.com

Vericel at BofA Securities Conference: Growth and Innovation in Healthcare

May 17, 2025 | investing.com

Vericel Co. (NASDAQ:VCEL) Given Consensus Rating of "Buy" by Brokerages

May 15, 2025 | marketbeat.com

StockNews.com Downgrades Vericel (NASDAQ:VCEL) to Sell

May 15, 2025 | marketbeat.com

Northern Trust Corp Buys 44,397 Shares of Vericel Co. (NASDAQ:VCEL)

May 13, 2025 | marketbeat.com

Leerink Partnrs Has Positive Outlook of Vericel Q4 Earnings

May 13, 2025 | marketbeat.com

Vericel (NASDAQ:VCEL) Issues Earnings Results

May 12, 2025 | marketbeat.com

First Trust Advisors LP Lowers Stock Holdings in Vericel Co. (NASDAQ:VCEL)

May 12, 2025 | marketbeat.com

Frontier Capital Management Co. LLC Has $15.82 Million Stock Holdings in Vericel Co. (NASDAQ:VCEL)

May 11, 2025 | marketbeat.com

Which Is a Better Investment, BioCryst Pharmaceuticals, Inc. or Vericel Corporation Stock?

May 10, 2025 | aaii.com

Hsbc Holdings PLC Acquires New Position in Vericel Co. (NASDAQ:VCEL)

May 10, 2025 | marketbeat.com

Vericel Corporation: Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability Guidance

May 9, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCEL, ROIV, RVMD, and BPMC Company Descriptions

Blueprint Medicines NASDAQ:BPMC

$103.06 +7.76 (+8.14%)

Closing price 04:00 PM Eastern

Extended Trading

$102.40 -0.66 (-0.64%)

As of 04:18 PM Eastern

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Roivant Sciences NASDAQ:ROIV

$11.30 +0.68 (+6.40%)

Closing price 04:00 PM Eastern

Extended Trading

$11.26 -0.04 (-0.35%)

As of 05:04 PM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Revolution Medicines NASDAQ:RVMD

$39.08 +1.35 (+3.58%)

Closing price 04:00 PM Eastern

Extended Trading

$39.10 +0.02 (+0.04%)

As of 04:49 PM Eastern

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Vericel NASDAQ:VCEL

$41.35 -0.75 (-1.78%)

Closing price 04:00 PM Eastern

Extended Trading

$41.36 +0.01 (+0.02%)

As of 04:32 PM Eastern

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time